Log In
Print
BCIQ
Print
Print this Print this
 

TK, Zalmoxis (HSV-TK) (formerly TBI-0301)

  Manage Alerts
Collapse Summary General Information
Company MolMed S.p.A.
DescriptionDonor lymphocytes engineered to express human herpes simplex thymidine kinase suicide gene
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentRegistration
Standard IndicationLeukemia
Indication DetailsFacilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT); Treat leukemia
Regulatory Designation U.S. - Orphan Drug (Facilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT));
EU - Orphan Drug (Facilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT));
EU - Standard Review (Facilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT))
Partner Takara Bio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today